Clinical Trial Update: Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating melphalan, bortezomib, and autologous stem cell transplant for primary systemic amyloidosis; results were posted in February 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Amyloidosis

Drugs mentioned

• Bortezomib (bortezomib)
• Melphalan (Melphalan)

Snippet

Sponsor: Boston Medical Center | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2017-02-06